ABIVAX
€83.50Change from previous close: −0.77%Absolute change: −€0.65
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -161 | -154 | -97.1 | -53.9 | — |
| Depreciation and amortization | 1.1 | 1.1 | 0.7 | 0.5 | — |
| Capital expenditure | -0.1 | -0.6 | -0.3 | -0.3 | — |
| Investing cash flow | -8.2 | 15.8 | -8.1 | -12.0 | — |
| Financing cash flow | 547 | 28.2 | 335 | 32.2 | — |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Debt issued | 0.0 | 47.9 | 55.8 | 0.0 | — |
| Debt repaid | -59.5 | -10.5 | -40.6 | -9.7 | — |
| Effect of exchange rates | -10.3 | 2.4 | -5.1 | 0.0 | — |
| Net change in cash | 383 | -110 | 230 | -33.8 | — |
| Free cash flow | -161 | -155 | -97.4 | -54.3 | — |